Glucagon-like peptide 1 (GLP-1) is an endogenous peptide hormone that binds GLP-1 receptors, increasing cAMP and insulin secretion. GLP-1 primarily exhibits anorexigenic, anti-diabetic, and gastrointestinal modulatory activities. GLP-1 decreases food intake and glucagon levels in animal models and also slows gastric emptying. In subjects with type 2 diabetes, the response of GLP-1 to glucose is impaired and subjects show abnormally low levels of GLPs.
| Cas No. | 106612-94-6 |
|---|---|
| Purity | ≥95% |
| Formula | C151H228N40O47 |
| Formula Wt. | 3355.67 |
| Synonym | Insulinotropin, Tglp-1; GLP-1 |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | G4482 Info Sheet PDF |
|---|
Kim S, Wan Kim S, Bae YH. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets. Biomaterials. 2005 Jun;26(17):3597-606. PMID: 15621250.
Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab. 2003 Apr;88(4):1772-9. PMID: 12679472.
Mannucci E, Ognibene A, Cremasco F, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med. 2000 Oct;17(10):713-9. PMID: 11110504.
Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol. 1998 Oct;35(3):117-29. PMID: 9840447.
